

UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Edith Ramirez, Chairwoman
Julie Brill
Maureen K. Ohlhausen
Joshua D. Wright

In the Matter of)	
)	
MYLAN INC.,)	
a corporation;)	
)	
AGILA SPECIALTIES GLOBAL PTE. LIMITED,)	
a corporation;)	
)	
AGILA SPECIALTIES PRIVATE LIMITED,)	Docket No. C-4413
a corporation;)	
)	
and)	
)	
STRIDES ARCOLAB LIMITED,)	
a corporation.)	

COMPLAINT

Pursuant to the Clayton Act and the Federal Trade Commission Act, and its authority thereunder, the Federal Trade Commission (“Commission”), having reason to believe that Mylan Inc. (“Mylan”), a corporation su

2. Respondent Agila Specialties Global Pte. Limited, a wholly owned subsidiary of Strides, is a corporation organized, existing, and doing business unde

- i. ganciclovir injection;
- j. meropenem injection; and
- k.

VIII. VIOLATIONS CHARGED

22. The Agreement described in Paragraph 6 constitutes a violation of Section 5 of the FTC Act, as amended, 15 U.S.C. § 45.

23. The Acquisition described in Paragraph 6, if consummated, would constitute a violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the FTC Act, as amended, 15 U.S.C. § 45.

WHEREFORE, THE PREMISES CONSIDERED, the Federal Trade Commission on this twenty-sixth day of September 2013, issues its Complaint against said Respondent.

By the Commission.

Donald S. Clark
Secretary

SEAL: